New Medication for Uncontrolled Eczema

Trial Objective

Our researchers are studying a new medication called dupilumab to determine how it affects the immune system, water loss in the skin, and the amount of bacteria in the skin of adults with atopic dermatitis (eczema).

New Medication for Uncontrolled Eczema

People with chronic atopic dermatitis have dry, scaly, itchy skin and often have repeat viral and bacterial skin infections. A bacteria known as Staph aureus, or Staph, causes many of these infections. To control their symptoms, many people with atopic dermatitis use long-term topical or oral treatments. Long-term use of these medications can have side effects. For this reason, new treatments are being researched, especially for patients whose symptoms are not controlled by existing medications. The Food and Drug Administration recently approved dupilumab for moderate-to-severe atopic dermatitis.


This trial is active and currently recruiting.

How to Participate

For more information, contact Caroline Bronchick at 303.398.1409 or complete the form below.

Who Can Participate

Adults who have had chronic atopic dermatitis for at least three years, have it on more than 10 percent of their body, and have at least three active lesions that measure at least 4-by-4 centimeters on  their arms or legs may be eligible to participate. 

Estimated Time Commitment

10 visits and 1 telephone call over about 6-7 months

Trial Location

National Jewish Main Campus, Denver, CO



Trial Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)




Any Gender

Request More Information